← Back to All Filings

Avidity (RNA) CHRO Sells $1.24M in Stock for Tax Withholding

Low SignificanceDecember 19, 2025 at 8:32:36 AM EST

Avidity Biosciences, Inc.

$RNA4CIK: 0001599901

Subscribe to track RNA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Avidity (RNA) CHRO Sells $1.24M in Stock for Tax Withholding

Company: Avidity Biosciences, Inc. (RNA) Form: 4 | Filed: 2025-12-19 Significance: Low

Insider: McCarthy Teresa Title: Chief Human Resources Officer | Relationship: Officer

Transaction: • Type: Tax Withholding Sale • Shares: 17,298 • Price: $71.87 • Value: $1,243,261 • Owned After: 118,832

Key Insight: The sale was to cover tax obligations from the vesting of 39,000 performance-based stock units (PSUs). This is a routine, non-discretionary transaction.

Market Context: The transaction value represents approximately 0.012% of Avidity's $10.67B market capitalization, indicating it is not material.

Comprehensive Analysis

SEC Filing Analysis: Avidity Biosciences, Inc. (RNA)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Human Resources Officer disposed of shares in a non-discretionary transaction to cover tax liabilities arising from the vesting of performance-based restricted stock units (PSUs).
  • Market Impact: The transaction is routine and represents a negligible fraction of the company's market capitalization, suggesting a neutral market impact.

Company Information

FieldValue
CompanyAvidity Biosciences, Inc.
Ticker SymbolRNA
CIK0001599901
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameMcCarthy Teresa
CIK0001862121
Title/PositionChief Human Resources Officer
RelationshipOfficer

Transaction Details

This filing reports two transactions: an acquisition of 39,000 shares from vested PSUs (Code A) and a disposition of 17,298 shares to cover taxes (Code F). The analysis focuses on the disposition as it has a monetary value.

FieldValue
Form Type4
Transaction Date2025-12-17
Transaction CodeF (Payment of tax liability by withholding security)
Security TypeCommon Stock
Shares Involved17,298
Price Per Share$71.87
Total Value$1,243,260.66
Shares Owned After118,832
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,243,260.66
% of Market Cap0.012%
Shares Transacted17,298
% of Shares OutstandingN/A (Data not available)
Post-Transaction Ownership118,832 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $10.67 billion, a transaction of $1.24 million is financially immaterial.
  • Transaction Significance: The sale represents a very small percentage (0.012%) of the company's market value. Such 'sell-to-cover' transactions are common for executives to manage tax obligations from equity compensation and are not typically indicative of a change in an insider's outlook on the company.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is a non-discretionary sale to cover taxes, not a voluntary sale based on market sentiment. Its small size relative to the company's market cap further supports a neutral outlook.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The transaction is not large enough to significantly impact trading volume.
  • Sentiment Indicator: Neutral. The filing is unlikely to influence investor sentiment as it reflects a standard compensation-related event.

Additional Context

Transaction Notes

  • Special Circumstances: The filing's footnotes explicitly state the disposition (Code 'F') was to cover tax withholding obligations related to the vesting of PSUs. The insider's net position increased by 21,702 shares (39,000 acquired - 17,298 disposed).
Topics:#SECFiling#InsiderTrading#RNA#AvidityBiosciences#Form4#SellToCover#Biotech#StockMarket#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.